Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 6, 26 | -0.17 Increased by +47.04% | -0.15 Decreased by -13.33% |
| Dec 31, 25 | -0.17 Increased by +46.88% | -0.17 Increased by +2.86% |
| Nov 14, 25 | -0.19 Increased by +61.22% | -0.34 Increased by +44.12% |
| Aug 14, 25 | -0.20 Increased by +62.26% | -0.37 Increased by +45.95% |
| May 12, 25 | -0.32 Increased by +17.69% | -0.54 Increased by +40.56% |
| Mar 26, 25 | -0.32 Increased by +27.27% | -0.53 Increased by +39.62% |
| Nov 11, 24 | -0.49 Decreased by -19.51% | -0.57 Increased by +14.04% |
| Aug 14, 24 | -0.53 Decreased by -29.27% | -0.48 Decreased by -10.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 225.00 K Increased by +N/A% | -2.30 M Increased by +0.09% | Decreased by -1.02 K% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -2.43 M Increased by +25.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.05 M Increased by +58.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.06 M Increased by +61.54% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.30 M Increased by +41.84% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 136.00 K Decreased by -5.56% | -3.27 M Increased by +26.84% | Decreased by -2.40 K% Increased by +22.53% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.94 M Decreased by -18.58% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.34 M Decreased by -28.25% | Decreased by N/A% Decreased by N/A% |